3 - ENvue Medical, Inc. (0001326706) (Issuer)

3 - ENvue Medical, Inc. (0001326706) (Issuer)

TYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the signing of a distribution agreement with U-Deliver to distribute ENvue's recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels. "We believe that our partnership with U-Deliver is an important step in scaling ENvue's over-the-counter ENFit syringe line and strengthening our presence in the non-acute enteral care marke

TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

TYLER, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a line of over-the-counter ENFit Syringes designed to meet both feeding and medication delivery clinical needs. "As care continues to shift beyond the hospital setting, providers and caregivers need reliable, high-quality solutions that support patients throughout the entire care journey," said Doron Besser, MD, CEO of ENvue Medical. "With the launch of our over-the-

TYLER, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing on the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a new development and integration program leveraging vibration-based technology from its NanoVibronix division to address pain and discomfort associated with indwelling nasogastric (NG) tubes. Nasogastric tubes are among the most widely used devices in hospital care and are frequently required to remain in place for extended periods. While clinically essential, indwe

TYLER, Texas, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems including enteral access solutions and non-opioid pain management, today announced the Company will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in Times Square, New York, on Wednesday, January 14, 2026. The ceremony will be led by Doron Besser, MD, Chief Executive Officer of ENvue Medical, accompanied by members of the Company's leadership team, the Directors, employees, and key stakeholders who have been essential to the Company's growth and advancement. "Ringin

TYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK. In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial demand fol

TYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK. In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial demand following NHS Dru

ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

8-K - ENvue Medical, Inc. (0001326706) (Filer)

8-K - ENvue Medical, Inc. (0001326706) (Filer)

8-K - ENvue Medical, Inc. (0001326706) (Filer)

EFFECT - ENvue Medical, Inc. (0001326706) (Filer)

TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h